Lercanidipine Actavis

Lercanidipine, the active ingredient in Lercanidipine Actavis, is a calcium channel blocker presented as a tablet for oral use. It treats hypertension in adult patients by lowering elevated blood pressure.

GNH USA supplies Lercanidipine Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is used to manage conditions within the cardiovascular disease pathway, primarily hypertension. - Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications. - Essential hypertension: provides sustained blood pressure control in primary hypertension. - Isolated systolic hypertension: lowers elevated systolic pressure, especially in older adults.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity, often occurring early in therapy. - Flushing: sensation of warmth and redness, usually transient. - Peripheral edema: swelling of ankles or feet due to fluid accumulation. - Dizziness: may occur when standing quickly.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, pruritus, or urticaria. - Angioedema: swelling of face, lips, or throat, potentially life‑threatening.

Before initiating therapy, consider the following safety measures. - Renal impairment: monitor renal function and blood pressure closely. - Hepatic impairment: use with caution; dose adjustment may be required. - Concomitant CYP3A4 inhibitors: anticipate increased plasma levels and possible hypotension. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Elderly patients: start at low dose and monitor for orthostatic hypotension. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may cause excessive blood pressure reduction. - Combined use with other antihypertensives (e.g., ACE inhibitors, diuretics): risk of additive hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Grapefruit juice: can increase plasma concentration of lercanidipine. - Beta‑blockers: monitor heart rate and blood pressure for additive effects.